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Abstract
The oncogene FOXM1 has been implicated in all major types of human cancer. We recently showed that aberrant FOXM1
expression causes stem cell compartment expansion resulting in the initiation of hyperplasia. We have previously shown
that FOXM1 regulates HELLS, a SNF2/helicase involved in DNA methylation, implicating FOXM1 in epigenetic regulation.
Here, we have demonstrated using primary normal human oral keratinocytes (NOK) that upregulation of FOXM1 suppressed
the tumour suppressor gene p16INK4A (CDKN2A) through promoter hypermethylation. Knockdown of HELLS using siRNA re-
activated the mRNA expression of p16INK4A and concomitant downregulation of two DNA methyltransferases DNMT1 and
DNMT3B. The dose-dependent upregulation of endogenous FOXM1 (isoform B) expression during tumour progression
across a panel of normal primary NOK strains (n = 8), dysplasias (n = 5) and head and neck squamous cell carcinoma (HNSCC)
cell lines (n = 11) correlated positively with endogenous expressions of HELLS, BMI1, DNMT1 and DNMT3B and negatively
with p16INK4A and involucrin. Bisulfite modification and methylation-specific promoter analysis using absolute quantitative
PCR (MS-qPCR) showed that upregulation of FOXM1 significantly induced p16INK4A promoter hypermethylation (10-fold,
P,0.05) in primary NOK cells. Using a non-bias genome-wide promoter methylation microarray profiling method, we
revealed that aberrant FOXM1 expression in primary NOK induced a global hypomethylation pattern similar to that found in
an HNSCC (SCC15) cell line. Following validation experiments using absolute qPCR, we have identified a set of differentially
methylated genes, found to be inversely correlated with in vivo mRNA expression levels of clinical HNSCC tumour biopsy
samples. This study provided the first evidence, using primary normal human cells and tumour tissues, that aberrant
upregulation of FOXM1 orchestrated a DNA methylation signature that mimics the cancer methylome landscape, from
which we have identified a unique FOXM1-induced epigenetic signature which may have clinical translational potentials as
biomarkers for early cancer screening, diagnostic and/or therapeutic interventions.
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Introduction
Understanding the epigenetic mechanism regulating stem-cell
fate determination provides fundamental insights into the
physiology of tissue regeneration and pathogenesis of cancers.
The best studied epigenetic mechanism perturbed during cancer
initiation and progression is DNA methylation which chemically
adds methyl groups to cytosines at their 59 positions, predomi-
nantly at CpG dinucleotides in the mammalian genomic DNA [1].
DNA methylation involves three key DNA methyltransferases:
DNMT1, DNMT3A and DNMT3B. DNMT1 has classically been
implicated in maintenance of existing methylated DNA, whereas,
DNMT3A and DNTM3B in de novo DNA methylation [1]. The
heritable nature of DNA methylation enables cells to determine
cell potency/fate without changing the primary sequence of
genomic DNA. The reversibility of DNA methylation program-
ming renders cell fate specification highly plastic and reversible.
Epigenetic reprogramming involving changes in DNA methylation
has been implicated in all stages of cancer evolution [2,3]. It has
also been shown that epigenetic reprogramming precedes the
initiation of cancer-like stem/progenitor cells [4]. It is now well-
accepted that cancer cells exploit the reversible and heritable
properties of DNA methylation to perturb the balance between
stem/progenitor cell renewal and differentiation thereby promot-
ing cancer initiation and progression [2,3,4].
FOXM1 (isoform B) was first found to be a downstream tar-
get of an oncogenic Sonic Hedgehog signalling pathway via a
glioma family zinc finger transcription factor 1 (Gli1) in basal cell
carcinomas [5]. Subsequent studies revealed that FOXM1 was
ubiquitously upregulated in the majority of human cancers [6,7]
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which include brain, liver, breast, lung, stomach, pancreas, colon,
kidney, bladder, prostate, testis, ovary, uterus, cervix, blood (acute
myeloid leukaemia), cutaneous melanoma, head and neck
squamous cell carcinomas [8,9].
In the quest to understand the oncogenic mechanism of
FOXM1, we have recently shown that FOXM1 induces cancer
initiation by promoting adult human epithelial stem/progenitor
cell renewal and by antagonising differentiation [10]. Others have
demonstrated that FOXM1 plays a key role in maintaining stem/
progenitor cell renewal through pluripotency genes including Oct4,
Nanog, Sox2 and Bmi1 [11,12]. Our previous work identified a
FOXM1 downstream target HELLS [8], a human embryonic stem
cell factor/lymphoid-specific SNF2/helicase involved in chroma-
tin remodelling and DNA methylation [13,14], implicating
FOXM1 in epigenetic regulation during stem/progenitor cell
renewal [8,10]. However, it was unclear whether FOXM1 has
a role in epigenetic regulation. In this study, using primary
normal human oral keratinocytes and head and neck squa-
mous cell carcinoma (HNSCC) tumour cell lines and tumour
biopsy tissues, we investigated the role of FOXM1 in the
regulation of gene promoter methylation at both single gene and
genome-wide levels. This led to the first evidence in normal
primary human oral epithelial cells that FOXM1 induces a
methylation landscape resembling a cancer epigenome found in
HNSCC tumour tissues.
Methods
Clinical Tissues
The use of human tissue in this study has been approved by our
host institutions (Barts & the London NHS Trust and the School of
Medicine & Dentistry, Queen Mary University of London) and the
UK National Research Ethics Committee. All clinical samples,
which were surplus to diagnosis, were collected according to local
ethical committee-approved protocols and written informed
patient consent was obtained from all participants. Pairs of normal
margin and HNSCC tumour core tissue biopsies were histopath-
ological pre-validated by our collaborating pathologists prior to
use for this study. Fresh biopsy tissue samples were preserved in
RNALater (Cat# AM7022, Ambion, Applied Biosystems, War-
rington, UK) and stored short-term at either 4uC (1–2 days) or
220uC (up to 1 week) prior to transportation and subsequent long-
term storage at 280uC until use.
Cell culture
All primary normal human oral keratinocytes (OK355, HOKG,
OK113, NOK, NOK1, NOK3, NOK16 and NOK376) were
extracted from normal oral mucosa tissues donated by healthy
disease-free individuals undergoing wisdom tooth extraction and
cultured as previously described [8,15]. Oral dysplastic precancer
cell lines (OKF6/T [16], POE9n [17], DOK [18], D19 [19], D20
[19]) and oral SCC cell lines (SCC4 [20], SCC9 [20], SCC15
[20], SCC25 [20], SqCC/Y1 [21], UK1 [22], VB6 [22], CaLH2
[22], CaDec12 [22], 5PT [22], H357 [22]), SVpgC2a [23] and
SVFN1-8 [8] were all well-established cell lines cultured as
described previously [8,10,15].
Immunoblotting
Protein extraction and separation on SDS-PAGE gels and
immunoblotting was performed as previously described (5). A mouse
monoclonal antibody for p16INK4A (1:2000 dilution; Cat# 551154,
BD Biosciences) and a rabbit polyclonal anti-GAPDH (1:20,000
dilution; Cat# 9485, Abcam) were used for immunoblotting.
RNA interference
Pre-validated gene-specific siHELLS (ON-TARGETplus SMART-
pool HELLS, Cat# L-017444-09,10,11,12), control siCTRL (ON-
TARGETplus Non-targeting Pool, Cat# D-001810-10-05) and
siRNA transfection reagent (DharmaFECT 1, Cat# T-2001-02)
were purchased from Dharmacon, Thermo Fisher Scientific. An
initial dose-response experiment was performed according to
manufacturer’s instructions to determine the optimum transfection
efficiency. siRNA at 10 nM (48-hour incubation) was found to be
the optimum final concentration which was therefore used in all
subsequent experiments. The effect of gene silencing was validated
by quantification of the target gene mRNA expression (HELLS) by
absolute reverse transcription qPCR.
Retroviral transduction
Retroviral supernatant and transduction procedures were
performed using our established protocols [8,10,15]. Equal levels
of EGFP and FOXM1 (isoform B) expression were achieved by
serial retroviral supernatant titration experiment and subsequently
EGFP plasmid copy number confirmed by qPCR using genomic
DNA extracted from transduced cells according to our previously
established method [15]. The levels of ectopic FOXM1 expression
in the primary keratinocytes were titrated to replicate levels found
in cancer cells as reported previously [8,10,15] (see Figure 1C).
Transduced cells were cultured for 3–5 days to allow transgene
expression prior to experiment.
Nucleic Acids Preparations from Tissues and Cells
All tissue biopsies were digested by proteinase K (Cat#
03115887001, Roche Diagnostics Ltd., England, UK) prior to
simultaneous mRNA extraction (Dynabeads mRNA Direct kit,
Cat# 610.12, Invitrogen) and genomic DNA (gDNA) extraction
(by standard phenol:chloroform method on mRNA-depleted
lystates). mRNA was immediately reverse transcribed into cDNA
(Transcriptor cDNA Synthesis kit, Cat# 04897030001, Roche
Diagnostics). gDNA were fragmented by MseI digestion (37uC,
16 h) prior to enrichment for CpG-methylated DNA using a
MBD2b/MBD3L1-conjugated magnetic bead-based system ac-
cording to manufacturer’s protocol (MethylCollector Ultra kit,
Cat# 55005, Active Motif Europe, Belgium).
Genome-wide Promoter Methylation Profiling
According to manufacturer’s protocol and requirements, input
MseI-digested gDNA and methylation-enriched DNA from each
cell sample (NOKG, NOKF and SCC15) were amplified to
generate 6 mg DNA using WGA2 GenomePlex (Sigma) prior to
microarray experiments performed by Roche NimbleGen micro-
array service using Human DNA Methylation 3x720K CpG
Island Plus RefSeq Promoter Array (Cat# 05 924 600 001;
NimbleGen System, Reykjavik, Iceland) based on genome built
HG18, with promoter upstream/downstream tilling of 22.44/
+0.61 kb, covering a total of 27,728 CpG islands across the whole
genome (GEO Platform: GPL14361). Microarray data generated
in this study is MIAME compliant and has been deposited in a
MIAME compliant database at Gene Expression Omnibus
repository (GEO Series accession number: GSE31767).
Real-time absolute quantitative PCR
Standard curve-based real-time absolute quantitative PCR were
performed using SYBR Green I Master (Cat# 04887352001,
Roche Diagnostics Ltd, England, UK) in the 384-well LightCycler
480 qPCR system (Roche) according to our established protocols
[8,9,15] which are MIQE compliant [24]. Methylation-specific
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PCR conditions were performed as described previously [25,26].
All primers used in this study are listed in Figure S1. Previously
validated isoform B-specific FOXM1 primers were used to
specifically quantify FOXM1 (isoform B) mRNA expression in
this study [8]. All target genes were normalised to two stable
reference genes (YAP1 and POLR2A) previously validated to be
amongst the most stable reference genes across a wide variety of
primary human oral cells, dysplastic and HNSCC cell lines [8].
Results and Discussion
Given our previous finding that FOXM1 (isoform B) promoted
stem/progenitor cell renewal through perturbing the differentia-
tion pathway [10], we initially questioned the involvement of a
tumour suppressor gene p16INK4A (CDKN2A) given that it has been
shown to regulate epithelial stem/progenitor cell differentiation
[27] and it is the most commonly inactivated gene in cancer [28].
Here, we showed that ectopic FOXM1 expression suppressed both
mRNA and protein expression of p16INK4A in primary human
oral keratinocytes (Figure 1A). Unfortunately, as reported
previously silencing endogenous FOXM1 expression causes cell
cycle arrest [29] which precluded further experiments using RNAi
on the notoriously sensitive primary human oral keratinocytes
[8,10]. Nevertheless, our FOXM1 overexpression experiments
conclusively showed that FOXM1 upregulation suppressed
p16INK4A gene expression in primary human oral keratinocytes.
This is in agreement with previous findings that FOXM1
suppresses the senescence pathway mediated by p16INK4A in
cancer cells [30].
Inactivation of p16INK4A gene expression could be a result of a
number of mechanisms including gene deletion and promoter
hypermethylation. Given that FOXM1 targets HELLS which
regulates DNA methylation [13,14], we hypothesised that
FOXM1 may be suppressing p16INK4A expression through
promoter hypermethylation via HELLS. To test this, we knock-
eddown HELLS by siRNA in an HNSCC cell line SVFN5, a
FOXM1-induced transformed oral buccal keratinocyte SVpgC2a
line [8], that expresses high levels of endogenous HELLS and low
levels of p16INK4A. This causes re-activation of the mRNA
expression of p16INK4A (Figure 1B) and concomitant downregula-
tion of two DNA methyltransferases DNMT1 and DNMT3B but
no effect on DNMT3A expression. The fact that p16INK4A
inhibition could be reactivated argues against gene deletion as a
mechanism for p16INK4A inactivation. Our results are consistent
with previous findings that HELLS interacts with DNMT1 and
DNMT3B [31] to suppress p16INK4A gene expression [32] through
epigenetic modifications.
To further validate that the expression of FOXM1, HELLS and
p16INK4A genes correlate with cancer progression and whether there
are any associations with genes involved in DNA methylation, we
measured the endogenous mRNA expression levels of FOXM1,
p16INK4A, HELLS, BMI1, involucrin (IVL, a differentiation marker
has been shown to be negatively regulated by FOXM1 [10]) and 3
key DNA methyltransferases (DNMT1, DNMT3A, DNMT3B) in a
panel of 24 cell strains/lines consisting of 8 strains of primary
normal human oral keratinocytes (from normal oral mucosa tissues),
5 dysplasia and 11 HNSCC cell lines.
In agreement with previous findings [8,10], FOXM1 showed
dose-dependent upregulation during tumour progression from
dysplasia to HNSCC (Figure 1C). Across the panel of 24 cell
strains/lines, we have found that the endogenous mRNA
expression of FOXM1 correlated inversely with p16INK4A but
correlation efficiency was weak (R2= 0.23, Figure 1D). The
downregulation of p16INK4A expression was found to be more
pronounced in dysplastic compared to HNSCC cell lines. Such
p16INK4A expression pattern is in complete agreement with in vivo
p16INK4A protein expression pattern found in oral dysplasia and
SCC tissues [33]. Consistently, BMI1, a polycomb group oncogene
which is an upstream regulator of p16INK4A gene [34] and also a
downstream target of FOXM1 [12,30], showed positive co-
expression with FOXM1 (R2= 0.64, Figure 1E) but weak inverse
correlation with p16INK4A (R2= 0.42, data not shown) supports the
evidence that p16INK4A expression is independently regulated by
BMI1 during oral carcinogenesis [35]. The discordant expression
levels between FOXM1 and p16INK4A in cancer cells may be due to
the fact that p16INK4A can be deregulated through a number of
different mechanisms, such as inactivating mutation (may result in
upregulation due to feedback mechanism), gene deletion, gene
amplification (of functional gene but defective downstream
signalling), promoter hypermethylation, etc. This may result in
varying p16INK4A expression independent of FOXM1 levels in the
‘‘cancer’’ cell lines. Hence, whilst FOXM1 can induce promoter
hypermethylation of p16INK4A in ‘‘normal’’ cells, such effect may be
perturbed in ‘‘cancer’’ cells.
Expression of DNMT1 (R2 = 0.84; Figure 1H) and DNMT3B
(R2 = 0.89; Figure 1J), but not DNMT3A (R2 = 0.13; Figure 1I),
showed significant positive co-expression with FOXM1 which are
in agreement with our findings above (Figure 1B) that silencing the
FOXM1-downstream target HELLS led to concomitant downreg-
ulation of DNMT1 and DNMT3B but no effect on DNMT3A
expression. It is unclear why DNMT3A was not affected. Published
literature indicates that although both DNMT3A and DNMT3B
are involved in de novo methyltransferase activity, they serve non-
overlapping roles [1]. Nevertheless, the involvement of both
DNMT1 and DNMT3B implicates a role for FOXM1 and HELLS
in triggering both maintenance and de novo DNA methylation
activities [1]. Expectedly, HELLS were positively (R2 = 0.76,
Figure 1F) and IVL were negatively (R2 = 0.52, Figure 1G)
correlated with FOXM1 as shown previously [8,9,10]. Collectively,
these results provide the first evidence in human cells that FOXM1
may be acting through HELLS, DNMT1 and DNMT3B to suppress
p16INK4A gene expression. Given that HELLS, DNMT1 and
DNMT3B have been previously shown to modulate p16INK4A
promoter methylation [31,32], we hypothesised that FOXM1 may
Figure 1. Upregulation of FOXM1 suppressed p16INK4A expression in primary human oral keratinocytes. (A) FOXM1 significantly
supresses p16INK4A mRNA and protein expression (inset figure) in primary normal human keratinocytes. GAPDH was used as a control for protein
loading. Control cells (mock-transduced with empty retroviral particles or EGFP-transduced) did not show significant suppression of p16INK4A
expression. (B) Knockdown of a FOXM1-target gene HELLS, which regulates genome-wide methylation [14], induced p16INK4A and simultaneously
suppressed DNMT1 and DNMT3B, but not DNMT3A mRNA expression in a FOXM1-transformed malignant cell line (SVFN5) expressing constitutive
levels of endogenous HELLS [8]. Each bar represents a mean 6 SEM of triplicate transfection (48 h) with either siCTRL or siHELLS. *P,0.05, **P,0.01
and ***P,0.001 indicate the level of statistical significance compared to controls. (C) Endogenous FOXM1 (isoform B) mRNA expression levels in 8
strains of primary human normal oral keratinocytes, 5 dysplastic and 11 HNSCC cell lines. Total FOXM1 mRNA expression levels were measured in the
EGFP and FOXM1-transduced NOK (NOKG and NOKF), respectively. (D–J) Third-order polynomial regression analyses were performed to obtain the R2
coefficient of determination values which indicate the significance of co-expression between each gene with FOXM1 across the 24 cell strains/lines
indicated in panel C.
doi:10.1371/journal.pone.0034329.g001
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be triggering p16INK4A gene silencing through promoter hyper-
methylation.
To investigate promoter CpG DNA methylation, we quantified
the level of p16INK4A promoter methylation using bisulfite
modification and methylation-specific quantitative PCR (MS-
qPCR; Figure 2A and Figure S1). Overexpression of FOXM1, but
not EGFP, was found to induce p16INK4A promoter hypermethyla-
tion (P,0.05) which was significantly reversed (P,0.001) by a
DNA demethylating agent 5-aza-29-deoxycytidine (5Aza) in
primary human oral keratinocytes (Figure 2B). These results
confirmed a role of FOXM1 in suppressing p16INK4A expression
through promoter hypermethylation. In support for FOXM1 in
initiating oncogenesis through the inhibition of p16INK4A, it has
been shown that epigenetic silencing of p16INK4A induces cellular
immortalisation in mouse embryonic fibroblasts [36]. Further-
more, our previous finding that FOXM1 expression co-expressed
with an epithelial stem cell marker DNp63a in the proliferating
stem/progenitor oral keratinocyte subpopulation [10], and that
DNp63a has been shown to target HELLS to induce squamous cell
carcinoma formation in mice [37], together suggest a possible role
for FOXM1 (via HELLS) in triggering oncogenesis through
silencing p16INK4A. The exact oncogenic mechanism is beyond
the scope of this study. Nevertheless, our current data providing
the first evidence that FOXM1 is able to induce promoter hyper-
methylation at a single gene level offers a glimpse of possibility that
aberrant upregulation of FOXM1 may perturb the epigenetic
regulation of DNA methylation at genome-wide level.
We and others have previously established a central role for
FOXM1 in the maintenance of genome stability whereby aberrant
FOXM1 expression causes global genomic instability [8,15,38].
Furthermore, the findings that FOXM1 targets an epigenetic/stem
cell modulator HELLS during cancer initiation [8,14] and FOXM1
directly induces p16INK4A promoter hypermethylation (Figure 2)
prompted us to hypothesise that aberrant upregulation of FOXM1
perturbs the methylome. To test this hypothesis, we performed a
non-bias genome-wide promoter methylation microarray profiling
on primary normal oral human keratinocytes (NOK) either
overexpressing a control gene EGFP (NOKG) or FOXM1 (NOKF)
(see Figure 1C for FOXM1 gene expression levels of NOKG and
NOKF cells), and also on an HNSCC cell line (SCC15). SCC15
was chosen in this study as a positive control because the promoter
of p16INK4A gene (CDKN2A) has been previously shown to be
hypermethylated and could be reactivated by 5Aza [39], hence
allowing us to validate the methylation array data. FOXM1 was
found to induce a global hypomethylation pattern similar to that
found in the HNSCC cell line, compared to control NOK cells
expressing EGFP (Figure 3A). Comparing the methylation patterns
by regression correlation analyses amongst the three cell types
(NOKG, NOKF and SCC15), only NOKF vs SCC15 gave a
positive correlation pattern, whereas NOKF or SCC15 each
produced an inverse correlation with the control NOKG
(Figure 3B). This indicates that overexpression of FOXM1, but not
EGFP, induces a methylation landscape similar to that found in
SCC15. Both global hypomethylation and focal hypermethylation
(affecting individual genes) are typical methylation patterns found in
cancer [2,3]. The fact that upregulation of FOXM1 induces these
methylation patterns in ‘‘normal’’ cells indicates that aberrant
expression of FOXM1 is changing the methylation landscape
towards those of cancer. The consequence of global hypomethyla-
tion has been shown to cause genomic instability [2,3], this may
provide a mechanism for our previous findings that aberrant
FOXM1 expression causes genomic instability in primary normal
human keratinocytes [8,15]. Although global hypomethylation
appeared to be the dominating effect, it has been shown that focal
hypermethylation silencing key tumour suppressor genes (eg.
p16INK4A) also plays important role in oncogenesis [2,3].
To validate our hypothesis that FOXM1-orchestrated a
methylation signature that mimics a cancer methylome, differen-
tially methylated genes (100 most hypomethylated and 100 most
hypermethylated) were initially selected for inverse comparisons
between NOKG and NOKF/SCC15, and a subset of 30
consensus genes, shared between NOKF and SCC15 cells, with
opposing methylation status to NOKG control cells, were
subsequently shortlisted for further analyses (Figure 3C). If these
candidate FOXM1-induced differentially methylated genes were
indeed an epigenetic signature of cancer, we hypothesised that
HNSCC tumour tissues should retain an inverse in vivo mRNA
expression signature of these candidate genes. To verify this, we
performed absolute qPCR to quantify each of the 30 candidate
genes: i, the relative levels of promoter DNA methylation of each
gene in NOKG vs NOKF cells, and, ii, the relative mRNA
expression levels in paired normal margin vs HNSCC tumour
tissue samples. Correlation regression analyses of the 30 candidate
genes showed an inverse relationship (R2= 0.62; Figure 3D, left
panel) between gene expression of HNSCC tumour tissues and
DNA methylation of NOKF cells.
Interestingly, hypomethylated genes showed significantly higher
inverse correlation pattern (R2 = 0.92; Figure 3D, right panel) than
the hypermethylated genes (R2= 0.27; Figure 3D, middle panel).
This suggests that promoter hypomethylation exhibited a stronger
effect on transcriptional activation compared to promoter
hypermethylation on transcriptional repression. One explanation
could be that it may be easier to detect transcriptional activation
following promoter hypomethylation as opposed to detecting
transcriptional repression which depends on whether the genes
were activated prior to hypermethylation. Our results indicate that
hypo/hypermethylation may not be a simple symmetrical on/off
switch for gene transcription. Further studies are required to
delineate the transcriptional mechanisms regulated by promoter
DNA methylation/demethylation.
Of the list of 15 novel FOXM1-induced hypermethylated genes
(Figure 3D, middle panel), 4 genes (C6orf136, MGAT1, NDUFA10
and PAFAH1B3) had significantly downregulated mRNA expression
levels in HNSCC tumours, along with the positive control p16INK4A
(CDKN2A). Little published gene information was available for
C6orf136. MGAT1 [mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-
acetyl-glucosaminyltransferase] has been implicated in glycerolipid
metabolism [40]; NDUFA10 (NADH dehydrogenase (ubiquinone)
Figure 2. FOXM1 induces promoter hypermethylation of p16INK4A gene in primary human oral keratinocytes. (A) Bisulfite modification
and methylation specific absolute qPCR for the quantification of p16INK4A promoter methylation status. Genomic DNA was first treated with sodium
bisulfite prior to PCR pre-amplification of the promoter region of p16INK4A (PCRBS, 273 bp). Methylation specific (p16M-R/F) and methylation-
independent (p16U-F/R) primers were then used to quantify the relative levels of methylated and unmethylated products within the PCRBS sample
using standard-curve based absolute qPCR method for each product, respectively. Melting analysis was performed to validate the qPCR specificity in
detecting the two M and U products. (B) Bisulfite conversion and methylation specific qPCR were performed to measure the relative levels of
unmethylated (U, melting temperature at 85.8uC) and methylated (M, 91.2uC) in either EGFP- or FOXM1-transduced primary NOK treated with either
vehicle (DMSO) or 5Aza (1 mM, 3-day incubation with fresh drug replenishment daily). A total of n = 11 replicates from at least 4 independent
experiments were performed. Statistical t-test significance notations *P,0.05 and ***P,0.001.
doi:10.1371/journal.pone.0034329.g002
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1 alpha subcomplex, 10, 42 kDa) in mitochondrial metabolism [41]
and PAFAH1B3 (platelet-activating factor acetylhydrolase 1b,
catalytic subunit 3, 29 kDa) in brain development [42] and
spermatogenesis [43]. Given that their gene expressions were
suppressed through promoter hypermethylation in tumour tissues,
we speculate that they may be tumour suppressor genes. However,
their roles in tumourigenesis remained to be investigated.
Of the list of 14 novel FOXM1-induced hypomethylated genes
(Figure 3D, right panel), 4 genes (SPCS1, FLNA, CHPF and
GLT8D1) had significantly upregulated mRNA expression levels in
HNSCC tumours. FLNA (filamin A, alpha), an actin-binding
protein involves in cytoskeletal/membrane remodelling and
cellular motility [44,45], has been implicated in melanomagenesis
[44,46], prostate [47,48,49], breast [50], lung [51], liver [52] and
ovarian cancers [53]. CHPF (chondroitin polymerizing factor),
involved in extracellular matrix regulation [54], has recently been
implicated in colorectal cancer [55]. SPCS1 (signal peptidase
complex subunit 1 homolog) and GLT8D1 (glycosyltransferase 8
domain containing 1) are located adjacent to each other at
chromosome 3p21.1. Given that their gene expressions were
upregulated in tumour tissues, we speculate that they may be
oncogenes. However, their roles in oncogenesis remained to be
investigated.
Collectively, these results confirmed that aberrant expression of
FOXM1 triggers genome-wide methylomic alterations that mimic
the in vivo cancer methylome of HNSCC tumour tissues. We
speculate that this may be a mechanism exploited by FOXM1 to
induce progenitor/stem cells expansion [10] through methylome
reprogramming to antagonise differentiation.
In summary, we have shown for the first time that aberrant
upregulation of a single oncogene FOXM1 in primary normal
human oral epithelial cells orchestrated a cancer-like methylome
landscape, from which we have identified a unique set of FOXM1-
induced differentially methylated genes. We further provided
evidence that their in vivo gene expression signatures were retained
in HNSCC tumour tissues. Given that epigenetic alteration
precedes gene expression, we speculate that the FOXM1-induced
differentially methylated genes have strong potential as epigenetic
biomarkers for early cancer screening, diagnostic, prognostic and/
or therapeutic interventions.
Supporting Information
Figure S1 Absolute qPCR primers. (A) Nucleotide sequence
of the bisulfite treated promoter region of p16INK4A and their
respective primer sequences used in this study. Details of qPCR
conditions were performed according to published methods
[25,26]. (B) qPCR primer sequences of the 30 candidate
FOXM1-induced differentially methylated genes. Colour shaded
loci indicate that the genes were adjacent or nearby. Promoter
CpG islands (CGI) for each gene are annotated as either ‘S’ (sense
strand), ‘AS’ (antisense strand) or ‘-’ (no CGI within promoter
region). All primer pairs produce a single melting peak. Standard
curves were generated for each gene for absolute quantification of
unknown samples according to protocols described previously [8].
(PDF)
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